Lepticure

Quick links to important sections

Lepticure

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lepticure

Property Description
Active ingredient Gabapentin
Form Oral capsule, oral tablet, oral solution
Pharmacological class Anticonvulsant, Gabapentinoid
Common use Stabilizing nerve over-activity
Origin Synthetic gamma-aminobutyric acid (GABA) analogue

What Type of Medicine is Gabapentin and How is it Classified?

Gabapentin is a synthetic, single-active-ingredient drug classified as an anticonvulsant and a Gabapentinoid, used for its effects on the central nervous system (CNS). Chemically, it is defined as a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), a feature confirmed by pharmacological studies. Gabapentin is an anticonvulsant medication that is thought to affect how nerves send messages to the brain and body, which explains its stabilizing influence on overactive neural pathways. This medicine is clinically recognized for its unique mechanism within the class of anti-seizure agents, differentiating it from medications that act directly on classical GABA receptors.

Composition, Forms, and General Therapeutic Purpose

The active ingredient is Gabapentin (1-(aminomethyl)cyclohexaneacetic acid), a compound whose stability is notable because it is eliminated by the kidney as the unchanged drug, avoiding significant hepatic metabolism. It is administered in several oral dosage forms, including capsules, standard tablets, and oral solution, utilizing an inert pharmaceutical excipient base. Gabapentin acts by binding to the auxiliary alpha2delta subunits of voltage-gated calcium channels. This action reduces the excessive release of excitatory neurotransmitters. In essence, this compound provides a specific mechanism for controlling neural hyperexcitability, making it a standard option for managing conditions characterized by chronic nerve over-activity.

What side effects are possible with Lepticure?

Possible Side Effects and Safety Information

The safety profile for Gabapentin (Lepticure) is officially structured by government regulatory agencies into categories based on the frequency and type of effects observed. These classifications reflect how the medicine's potential risks are communicated, separating common effects from rare, but serious, documented reactions.


Frequency-Classified Adverse Reactions

The most frequently documented side effects are classified as Very Common, meaning they may affect more than 1 in 10 individuals. These often include somnolence (drowsiness), dizziness, and ataxia (impaired coordination). Effects classified as Common include weight gain, peripheral edema (swelling), and various gastrointestinal disorders such as nausea and vomiting.

These effects often involve the Nervous System and are sometimes more pronounced at the start of treatment, potentially diminishing as use continues.


Serious Adverse Reactions and Regulatory Constraints

Official labeling highlights specific, serious adverse reactions due to their clinical importance. These include the documented risk of suicidal ideation and behavior, severe hypersensitivity reactions like DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), and respiratory depression, particularly when used with other Central Nervous System (CNS) depressants.

Regulatory documents also stipulate specific safety constraints for certain populations. Patients with renal impairment require an adjustment to the dosing schedule due to the medicine's elimination pathway. Additionally, the label notes that the abrupt discontinuation is not recommended as it may increase the frequency of seizures.

Overdose and Emergency Response

Lepticure overdose is characterized by an escalation of neurological effects documented in regulatory labeling. The primary clinical manifestations of overexposure include excessive drowsiness (somnolence), lethargy, ataxia (impaired coordination), and slurred speech (dysarthria). Other recognized signs may include double vision and gastrointestinal effects such as diarrhea and vomiting.

The most serious outcome officially documented is respiratory depression, which carries a documented risk of coma and death, especially when Lepticure is taken concurrently with other central nervous system (CNS) depressants, such as opioids. Regulators note that patients with pre-existing impaired renal function and elderly individuals may be at elevated risk of severe overexposure due to the drug’s primary elimination pathway through the kidneys.

Official regulatory guidance requires immediate action due to the potential for severe and life-threatening complications. Individuals must seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if severe symptoms involve difficulty breathing, unresponsiveness, or an inability to be awakened. Treatment is supportive in nature, as no specific antidote is known for Lepticure overexposure. In cases of severe toxicity, hemodialysis may be a documented management option to aid in drug removal.

Therapeutic Uses of Lepticure

Lepticure is commonly used to help manage symptoms related to heightened neurological activity across several distinct domains.

Its therapeutic applications are relevant for the management of chronic neuropathic pain (such as Postherpetic Neuralgia and painful diabetic neuropathy), the control of partial onset seizures in epilepsy, and relief from the disruptive manifestations of Restless Legs Syndrome (RLS).

“This medication is applied across domains where additional symptomatic support is needed to address chronic pain caused by damaged or overactive nerves.”

The medication plays a role in managing conditions characterized by periods of heightened symptoms of increased neurological activity. It assists with managing symptom clusters that may become intense or disruptive, specifically targeting sensations like burning, stabbing, or shooting. Lepticure provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load. For patients with partial onset seizures, it may assist with maintaining a sense of stability when symptoms are more noticeable, supporting patients during episodes of heightened discomfort. Similarly, for RLS, it assists with maintaining functional stability and contributes to support for patient comfort during periods of rest.


Quick Fact: Relief for Chronic Nerve Pain Lepticure is commonly used in clinical settings that involve acute or unstable symptom patterns, offering symptomatic support to address pain that persists long after conditions like shingles or diabetes-related nerve damage.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Lepticure?

The eligibility for using Lepticure (gabapentin) is strictly defined by official regulatory guidelines, covering absolute prohibitions and specific patient constraints.

Absolute Contraindication

The medicine is contraindicated (must not be used) in patients who have a confirmed history of hypersensitivity (allergic reaction) to gabapentin or any other component of the formulation.

Age-Group Eligibility

Lepticure is approved for adults for pain and seizure indications. For pediatric patients, use is established for partial onset seizures starting at 3 years of age for adjunctive therapy, with safety and efficacy not established in children under 3 years old. Use in older adults (65 years and over) is permitted but requires specific consideration due to expected decline in renal function.

Conditional and Restricted Use

  • Renal Impairment: Patients with compromised kidney function (renal impairment), including those undergoing hemodialysis, require a dosage adjustment because the medicine is primarily eliminated through the kidneys.
  • Pregnancy and Lactation: Use during these periods is conditional. Regulatory information states the medicine should be used only if the potential benefit justifies the potential risk to the fetus or nursing infant.

What should I know about interactions with other medicines?

Lepticure Interactions with other medicines and products


Clinically Significant Interactions

Concomitant use of Lepticure with other medicines or substances that depress the central nervous system (CNS) can lead to additive CNS depressant effects, which include severe drowsiness, profound sedation, respiratory depression, coma, and death. Because of this serious risk, the co-administration of Lepticure with opioid analgesics or opioid-containing cough medicines is strongly discouraged and must be reserved for patients for whom alternative treatments are inadequate. If co-prescribed, the dosage and duration of both drugs should be limited to the minimum necessary, and patients must be closely monitored.

Metabolic Interactions and Contraindications

Lepticure is primarily metabolized by the Cytochrome P450 3A (CYP 3A) enzyme system. Concomitant use with strong inhibitors of this enzyme significantly increases the concentration of Lepticure in the body, raising the risk of severe adverse reactions. Therefore, co-administration with strong CYP 3A inhibitors, such as certain azole antifungals (e.g., ketoconazole, itraconazole) and HIV protease inhibitors (e.g., ritonavir), is contraindicated and must be avoided. Separately, patients must avoid consuming alcohol while taking Lepticure due to the enhanced depressant effects.

Mechanism of Action

How Lepticure Works: Pharmacodynamic Mechanism

Lepticure (Gabapentin) operates via a unique pharmacodynamic mechanism that modulates signal transmission within the central nervous system, independent of classical gamma-aminobutyric acid ( GABA) receptor interaction.


Molecular Target: Modulation of Presynaptic Calcium Channel Subunits

The mechanism centers on high-affinity binding to the alpha2delta-1 auxiliary subunit of presynaptic Voltage-Gated Calcium Channels ( VGCCs). This interaction is a regulatory modulation that affects VGCC trafficking, thereby reducing the functional availability of the channels on the nerve terminal surface.


Cascade: Attenuation of Excitatory Neurotransmitter Release

The reduction in functional VGCC density attenuates the required inward flow of calcium ions ( Ca^2+) upon depolarization. This limits the excessive vesicular release of excitatory neurotransmitters, such as glutamate and substance P, from presynaptic terminals exhibiting increased signal transmission activity.


Systemic Effect: Suppression of Sustained Neuronal Firing

The resulting decrease in excitatory chemical messaging leads to a systemic reduction in overall neural excitation. This produces the physiological outcome of suppressed high-frequency neuronal firing within affected pathways, modulating sustained signal propagation.

Dosage and Administration Information

Lepticure (gabapentin) is administered exclusively by the oral route, available as immediate-release capsules, conventional tablets, and a solution. Its usage is structured around a precise dosing pattern that requires three daily administrations to maintain systemic concentration. The maximum time between any two doses must not exceed 12 hours to help ensure continuous concentration.

Therapy is initiated with a gradual upward titration of the dosage over the first few days. For adults, the typical daily maintenance dosage ranges from 900 mg to 3600 mg per day for partial onset seizures, administered in three divided doses. Dosing for postherpetic neuralgia is similarly increased up to 1800 mg per day, divided three times daily. The immediate-release oral dosage forms may be taken independently of meals, either with or without food.

A key procedural requirement is to separate Lepticure administration from antacids containing aluminum or magnesium by a minimum of two hours. Furthermore, due to the compound's sole reliance on renal excretion, dose adjustment is mandatory for adult patients with reduced kidney function (CrCl < 60 mL/min), with specific reduced daily amounts scaled according to creatinine clearance. When discontinuing the medicine, clinical practice requires a gradual tapering of the dose over a minimum period of one week.

Recent Clinical Evidence

Evidence for Use in Specific Indications

Lepticure was studied for its role in conditions involving chronic neuropathic pain, such as Postherpetic Neuralgia (PHN) and Painful Diabetic Neuropathy (DPN). Research relies on short-term, placebo-controlled Randomized Controlled Trials (RCTs) that monitored patient-reported outcomes describing perceived discomfort, pain intensity, and sleep interference. The evidence quality was evaluated as High for these two specific conditions, though follow-up durations were typically limited to only a few weeks.

Lepticure was evaluated in studies for its role in conditions characterized by fluctuating or episodic manifestations, particularly in studies exploring its role as an add-on therapy for partial onset seizures. Studies explored outcomes related to episodic or acute changes by monitoring the frequency of seizures and tracked the proportion of individuals achieving a ge50% reduction in seizure frequency. The evidence quality was evaluated as High for this add-on use, while data supporting its single-agent use (monotherapy) was observed in some studies to be moderate.

Studies explored the use of Lepticure in patients with Restless Legs Syndrome (RLS) using RCTs. These studies examined outcomes related to systemic or functional imbalance, specifically focusing on the change in symptoms measured by the IRLS Rating Scale and monitoring sleep patterns. The Evidence Level was characterized as Moderate by some guideline bodies; however, many core RLS trials used a specific prodrug formulation which has differing characteristics.


Research Gaps and Follow-up Limitations

The majority of the core research consists of studies with follow-up durations that were limited, meaning that long-term effects are not fully established regarding outcomes related to chronic use. The research landscape also includes studies that evaluated Lepticure in specific patient groups, such as pediatric patients who were studied as part of adjunctive treatment regimens and older adults for newly diagnosed focal seizures. However, data for certain groups remain insufficient, and comparative evidence is lacking against some newer medications across several indications.

Key Studies & References Gabapentin: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Lepticure (FAQ)

Q: Is Lepticure generally safe for older people, based on studies?

Official information indicates that use in older adults is permitted, but specific consideration is required. Regulatory information indicates that older adults are often considered to have reduced kidney function, which can affect the medicine’s clearance. This may necessitate a dosage adjustment. Older adults are also noted to be more susceptible to unwanted effects such as swelling or problems with walking and balance.

Q: Are there any common foods or drinks that should be avoided when taking Lepticure?

Regulatory documents describe that the consumption of alcohol must be avoided while taking this medicine due to the enhanced risk of central nervous system depressant effects, such as drowsiness and breathing difficulties. Additionally, Lepticure should not be taken within two hours of taking antacids that contain aluminum or magnesium, as these can affect how much of the medicine is absorbed.

Q: What does the official patient information say about taking Lepticure if you are planning a pregnancy?

According to regulatory information, the medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus or nursing infant. There is no specific official guidance provided in regulatory documents regarding pre-conception planning or fertility. The assessment of individual risk when planning a pregnancy remains a discussion for a healthcare provider.

Q: Are there any known interactions between Lepticure and common pain relievers?

Regulatory documents state that co-administration with opioid analgesics (a type of pain reliever) is strongly associated with an increased risk of severe breathing difficulties and profound sedation. Core labeling does not typically include information regarding clinically significant interactions with common non-opioid pain relievers, such as nonsteroidal anti-inflammatory drugs (NSAIDs).

Q: How quickly does Lepticure leave the body after you stop taking it?

Studies on how the drug is cleared from the body show that its elimination half-life is typically between 5 to 7 hours in individuals with normal kidney function. The half-life is the time it takes for half of the medicine to be cleared from the system. Because the medicine is cleared solely by the kidneys, this half-life can be significantly prolonged in people with reduced kidney function.

Q: Is Lepticure safe to use while breastfeeding, according to official guidelines?

Official regulatory documents indicate that Lepticure is excreted into human milk. Regulatory information indicates that the use of the medicine while breastfeeding is conditional, based on an assessment of whether the potential benefits outweigh the potential risks to the nursing infant.

Q: What official information is available regarding Lepticure and mood changes?

Official labeling warns that Lepticure, like all anti-epileptic medicines, can increase the risk of suicidal thoughts and behavior. Official documentation notes that monitoring is required for new or worsening signs of depression, anxiety, irritability, or other unusual changes in mood or behavior.

Q: What does 'contraindication' mean in the context of Lepticure?

A contraindication means that the medicine is not recommended for use in a specific circumstance because the risks are considered to outweigh the potential benefits. For Lepticure, an absolute contraindication is a confirmed history of allergy (hypersensitivity) to the drug or any of its components.

Q: Are there restrictions on driving or operating machinery while on Lepticure?

Official warnings note that patients should assess whether the common effects of dizziness or somnolence (drowsiness) impair their ability to perform tasks like driving or operating complex machinery. This assessment is required because these effects can significantly affect reaction time and coordination.

Q: What research is available on Lepticure's long-term effect on cognitive function?

The drug's official labeling indicates that some patients have reported adverse reactions related to cognitive function, such as memory loss and difficulty focusing. Given that core research had limited follow-up durations, the emergence of these cognitive effects highlights areas for ongoing safety surveillance.

Q: What is the mechanism of action of Lepticure, as described in simple terms?

Lepticure works by affecting the way nerves send messages to the brain and body. It achieves this by binding to a specific subunit of the calcium channels on nerve cells. This action helps to reduce excessive nerve activity or hyperexcitability, which is why it is used to stabilize nerve over-activity.

Q: How long does it typically take before someone starts to notice the effects of Lepticure?

Patient information from some regulatory agencies suggests that while the drug begins to work right away, it may take a few weeks before an individual feels the full, intended effects of the medicine. Because of the gradual introduction process often used, the time required to experience the full effect may vary.

Q: If I miss a dose of Lepticure, what is the official guidance?

The official guidance for certain immediate-release formulations states that if a dose is missed, it should generally be skipped, and the person should take the next dose at the next regularly scheduled time. Taking two doses together to compensate for a missed dose is not recommended. The maximum time between any two doses should not exceed 12 hours.

Q: Do regulatory bodies classify Lepticure as a controlled substance?

Lepticure is not a federally scheduled controlled substance in the United States. However, regulatory bodies in some individual U.S. states and countries (such as the UK and parts of Australia) have classified it as a controlled substance due to reports of misuse and abuse potential.

Q: Does Lepticure have a generic version available?

Yes, the active ingredient gabapentin is widely approved and available as a generic medicine in various forms. This indicates that generic versions of the active ingredient are widely available.

Q: Can people who have liver problems use Lepticure?

Official information indicates that Lepticure is not appreciably metabolized (broken down) by the liver. Therefore, no specific dosage adjustment is typically required for patients who have hepatic (liver) impairment. However, monitoring is noted for the rare, serious risk of DRESS (a severe hypersensitivity reaction), which has been documented to affect the liver.

Q: What kind of monitoring is typically recommended while taking Lepticure?

Regulatory documents describe that close monitoring is required for changes in mood or behavior. This is specifically required to detect the early emergence or worsening of suicidal thoughts or depression, which are serious adverse reactions associated with the medicine.

Q: Does Lepticure have a 'black box' warning from the FDA or equivalent agency?

The FDA does not impose a Black Box Warning on the main label for this medicine. However, the agency issued a strong safety warning in 2019 about the serious risk of respiratory depression (severe breathing difficulties) when Lepticure is taken together with opioids or other medicines that depress the central nervous system.

Q: How common are serious allergic reactions to Lepticure?

Serious allergic reactions, such as anaphylaxis and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), are considered rare but have been reported through post-marketing surveillance. A history of hypersensitivity to the drug is listed as an absolute contraindication for use.

Q: Is the effectiveness of Lepticure affected by a person's diet?

Official documents state that Lepticure may be taken with or without food. Food has only a small effect on how the drug is absorbed into the body, meaning that the timing of your dose relative to meals is not typically a factor in its overall effectiveness.

Q: Can Lepticure interact with herbal remedies like St. John's Wort?

Because both Lepticure and St. John's Wort can cause effects that depress the central nervous system, official guidance notes that taking them together may enhance the central nervous system depressant effects. This could lead to increased dizziness, drowsiness, and confusion.

Q: What are the signs that Lepticure might be having an effect?

The medicine is studied based on its ability to reduce symptoms. Signs of effectiveness are measured in clinical trials by a reduced frequency of seizures or an improvement in pain intensity and a reduction in sleep interference for nerve pain conditions. The signs of effect are specific to the condition being treated.

Q: Is Lepticure physically or psychologically habit-forming?

Regulatory agencies have documented reports of misuse and abuse of Lepticure. For this reason, patients are monitored for signs of developing tolerance (needing more for the same effect) or exhibiting drug-seeking behavior.

Q: Is Lepticure known to interact with birth control pills?

According to regulatory studies, Lepticure does not interact with standard regimens of combination hormonal birth control, specifically those containing norethindrone acetate and ethinyl estradiol. This suggests that the effectiveness of those oral contraceptives is not affected by this medicine.

How should Lepticure be stored and disposed of?

How to Store and Dispose of Lepticure?

Regulatory documents define specific conditions for storing and disposing of Lepticure (Gabapentin) to ensure product stability and safety.

Storage Requirements

Dosage Form Required Storage Condition Child Safety
Capsules/Tablets Store at Controlled Room Temperature (20 C to 25 C) in the original container, protected from moisture. Must be kept out of the sight and reach of children.
Oral Solution Must be refrigerated (2 C to 8 C) after opening and is stable for 56 days. Must be kept out of the sight and reach of children.

Disposal

Unused or expired Lepticure must not be thrown away via household waste or wastewater. Disposal must comply with local requirements for pharmaceutical waste, which often involves returning the product to a pharmacy or using a community take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lepticure found in:

A-Z Index: